Semaglutide vs Liraglutide

Liraglutide (Saxenda) was the first GLP-1 drug approved for obesity in the US, cleared by the FDA in 2014. For several years it was the leading pharmacological option for weight management. Semaglutide (Wegovy) changed that when it was approved in 2021 — with dramatically greater efficacy, a more convenient dosing schedule, and a cardiovascular outcomes label that liraglutide does not have. The practical question for most patients considering this comparison is whether to switch, and if so, when.

Same class, meaningfully different molecules

Both drugs are GLP-1 receptor agonists made by Novo Nordisk. They work through the same fundamental mechanism — mimicking the GLP-1 hormone to suppress appetite, slow gastric emptying, and stimulate glucose-dependent insulin secretion. The difference is in their half-lives and resulting potency at the receptor.

Liraglutide has a half-life of approximately 13 hours, which is why it requires daily injection. Semaglutide has a half-life of approximately seven days — achieved through albumin-binding modifications to the molecule — which is why it can be dosed once weekly. The longer half-life produces more sustained receptor engagement and greater overall effect on appetite and weight.

The head-to-head evidence

A 2022 randomised controlled trial directly compared semaglutide 2.4mg to liraglutide 3mg for weight loss over 68 weeks in adults with obesity. The results were unambiguous: semaglutide produced 15.8% average weight loss versus 6.4% for liraglutide. 55% of semaglutide participants lost at least 15% of their body weight, compared to 12% on liraglutide. The tolerability gap was also significant: 13.5% of semaglutide participants stopped due to side effects versus 27.6% on liraglutide. More weight loss, better tolerability, and once-weekly rather than daily injection. The comparison is not close.

Where liraglutide still gets prescribed

The efficacy gap is significant enough that liraglutide rarely wins a direct comparison for weight management today. But there are practical circumstances where it remains relevant.

Liraglutide has been on the market longer — nine years versus four for Wegovy — and some practitioners in certain markets have more comfort prescribing it. Insurance formularies in some plans still favour liraglutide through step therapy requirements, meaning patients must try and fail it before a Wegovy prescription is covered. And for paediatric patients, liraglutide (Saxenda) is FDA-approved for adolescents aged 12 and older, while Wegovy's paediatric approval covers the same age group but liraglutide has more real-world paediatric experience.

In the context of type 2 diabetes management, the equivalent comparison is Victoza (liraglutide 1.8mg) versus Ozempic (semaglutide up to 2mg). The same efficacy hierarchy applies — semaglutide produces greater A1C reduction and weight loss — but Victoza has the LEADER cardiovascular outcomes trial, which demonstrated a significant reduction in MACE. Ozempic has SUSTAIN-6 and SUSTAIN-7, which also showed cardiovascular benefit. Both drugs in the diabetes context have cardiovascular data; semaglutide's is generally considered stronger.

Switching from Saxenda to Wegovy

No washout period is required when switching from liraglutide to semaglutide. Prescribers typically start patients at the lowest semaglutide dose (0.25mg weekly) regardless of the liraglutide dose they were on, then titrate up on the standard schedule. The different mechanism of action does not require a transition period, and the improved tolerability of semaglutide means the titration is often more straightforward than the original liraglutide titration was.

Patients who tolerated liraglutide reasonably well generally tolerate semaglutide well. Patients who struggled significantly with liraglutide's GI side effects may find semaglutide more manageable given its lower discontinuation rate, though individual responses vary.

Who should consider switching to semaglutide